Neurizon Therapeutics Limited · ASX:NUZ

Neurizon Therapeutics — Bell Potter Healthcare Conference 2026

16 slides from Neurizon Therapeutics's conference presentation, Nov 19, 2026

  1. Slide 1: Bell Potter Healthcare Conference Presentation

    Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Bell Potter Healthcare Conference Presentation 19 November 2026 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” For personal use only or “the Company”), a late clinical-stage biotechnology c

  2. Slide 2: Advancing an oral ALS therapy toward a defining clinical readout

    rsonal use only Advancing an oral ALS therapy toward a defining clinical readout Bell Potter Healthcare Conference – 19 November 2026 Dr Chris Bremer, Chief Executive Officer ABN 35 094 006 023

  3. Slide 3: Disclaimer

    Disclaimer This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). This Future Matters disclaimer applies to the presentation and all information contained in it. It does not purport to contain all the information that a prospective investor may require in co

  4. Slide 4: Our Vision

    rsonal use only Our Vision To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases.

  5. Slide 5: Why look now

    Why look now A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection rsonal use only 1 2 Late Q2 2027 Clinical advancement Supply chain readiness for scale Expected topline from the 250- participant Phase 2/3 ALS trial. A 250-participant randomised Phase 2/3 enrolled Long-term su

  6. Slide 6: ALS is a rapidly progressive neurodegenerative disease with significant unmet need

    ALS is a rapidly progressive neurodegenerative disease with significant unmet need ALS contributes to progressive degeneration of motor neurons, leading to ALS AT A GLANCE rsonal use only increasing loss of voluntary muscle function SPEECH 2–5 YEARS ~90% Loss of ability to speak Typical life expecta

  7. Slide 7: TDP-43 dysfunction & aggregation links ALS pathology to motor neuron failure

    TDP-43 dysfunction & aggregation links ALS pathology to motor neuron failure In most ALS/MND, nuclear TDP-43 is lost and accumulates in the cytoplasm, disrupting RNA processing, axonal rsonal use only maintenance and communication with muscles TDP-43 IS LOST FROM THE NUCLEUS AND THE MOTOR NEURON–MUS

  8. Slide 8: Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND

    Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND NUZ-001 Enhances Protein Clearance Pathways to Remove Toxic Protein Aggregates Enhances protein clearance rsonal use only mechanisms (autophagy & proteosomal system) Consistent effects observed Restores NfL axonal health across models: an

  9. Slide 9: Phase 1b & Open Label Extension Results

    Phase 1b & Open Label Extension Results Preliminary Signals of Efficacy in ALSFRS-R and SVC Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC rsonal use only percent predicted (PP) when compared to matched

  10. Slide 10: NUZ-001 shows improved survival vs matched controls

    Phase 1b & Open Label Extension NUZ-001 shows improved survival vs matched controls rsonal use only NUZ-001 treatment resulted in statistically significantly longer survival of participants with ALS, (X2=11.35, p=0.00075), compared to matched controls1 from the PRO-ACT database2 Analysis* suggests t

  11. Slide 11: Regimen I is designed to investigate clinical benefit

    Regimen I is designed to investigate clinical benefit REGIMEN I AT A GLANCE WHY THESE DESIGN CHOICES MATTER rsonal use only Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol 36-week blinded period Participants 250 enrolled at close of recruitment (protocol e

  12. Slide 12: Cost and Capital Management

    Cost and Capital Management A simplified capital structure, fully funded1 structure to HEALEY topline in Q2 CY2027 No convertible notes on issue. Capital efficient program. Material non-dilutive funding. Near term readout rsonal use only SIMPLIFIED FUNDING STRUCTURE DISCIPLINED CAPITAL ALLOCATION NO

  13. Slide 13: ALS: high unmet need with significant value potential

    ALS: high unmet need with significant value potential Three decades of approvals have delivered limited clinical benefit rsonal use only Current US ALS treatment landscape Key ALS Value Reference Point: Shionogi – RADICAVA (2026) 2017 IV 1995 2022 ORAL 2023 4 2 US$2.5B RILUZOLE 1 RADICAVA® / RADICAV

  14. Slide 14: A roadmap to topline readout and beyond

    A roadmap to topline readout and beyond Multiple material developments converging over the coming quarters rsonal use only Q4 CY2026 CY2027 Q2 CY2027 Late Q2 CY2027 Post-topline Expanding Pre-Clinical Expanded Access Trial completion and HEALEY topline Regulatory Evidence opens database lock engagem

  15. Slide 15: Investment summary

    Investment summary A defining randomised readout in late Q2 CY2027, with groundwork in place rsonal use only 1 A 250-participant randomised Phase 2/3 in ALS, efficiently run Late Q2 2 Record enrolment within the HEALEY platform, in under five months CY2027 3 Early clinical signals that shaped the Ph

  16. Slide 16: Thank You

    rsonal use only Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com

Neurizon Therapeutics — Bell Potter Healthcare Conference 2026 on 6ix